
ARDT Stock Forecast & Price Target
ARDT Analyst Ratings
Bulls say
Ardent Health Inc reported a significant EBITDA of $143 million, marking a 46% year-over-year increase and improving its margin to 9.1%, which reflects a 240 basis point enhancement. The company also experienced a 2.9% growth in admissions, aligning with its full-year outlook, while contract labor costs improved and professional fees grew by 11% due to ongoing demand in anesthesia and radiology services. Overall, there are strong growth trends in the hospital sector, and Ardent's strategies in outpatient services indicate substantial opportunities for future earnings potential.
Bears say
Ardent Health Inc. reported an EBITDA of $143 million for the quarter, which, despite a year-over-year increase of 46%, fell 2% short of expectations due to a temporary boost from Kansas SDPs. Additionally, the company faced a significant revenue adjustment of $43 million linked to its transition to the Kodiak revenue cycle management platform, contributing to concerns about accounts receivable collectability and a conservative outlook on future revenue generation. Moreover, revised estimates indicate lowered EBITDA projections for 2025 and 2026, reflecting ongoing challenges related to denial reductions and professional fee headwinds, thus implying minimal or negative EBITDA growth moving forward.
This aggregate rating is based on analysts' research of Ardent Health Partners LLC and is not a guaranteed prediction by Public.com or investment advice.
ARDT Analyst Forecast & Price Prediction
Start investing in ARDT
Order type
Buy in
Order amount
Est. shares
0 shares